By otakuyassine3@gmail.com 
Immunome, Inc. (NASDAQ:IMNM – Get Free Report)’s stock price was down 5.7% during mid-day trading on Friday . The company traded as low as $10.47 and last traded at $10.47. Approximately 110,281 shares traded hands during mid-day trading, a decline of 86% from the average daily volume of 779,801 shares. The stock had previously closed at $11.10.
Analysts Set New Price Targets
A number of equities research analysts have recently commented on IMNM shares. Piper Sandler lowered their target price on Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Stephens started coverage on shares of Immunome in a research note on Friday, November 8th. They set an “overweight” rating and a $30.00 price target for the company. Finally, Wedbush reissued an “outperform” rating and set a $33.00 price objective on shares of Immunome in a report on Friday, October 25th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $28.83.
Immunome Trading Down 5.4 %
The company has a market cap of $655.38 million, a PE ratio of -1.29 and a beta of 1.83. The stock has a 50 day moving average price of $12.05 and a 200 day moving average price of $13.24.
Insider Transactions at Immunome
In other Immunome news, CEO Clay B. Siegall bought 66,057 shares of Immunome stock in a transaction on Thursday, November 21st. The stock was acquired at an average price of $9.54 per share, with a total value of $630,183.78. Following the acquisition, the chief executive officer now owns 485,693 shares in the company, valued at approximately $4,633,511.22. This trade represents a 15.74 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CTO Philip Tsai acquired 21,000 shares of the company’s stock in a transaction that occurred on Thursday, November 21st. The shares were acquired at an average cost of $9.43 per share, for a total transaction of $198,030.00. Following the completion of the transaction, the chief technology officer now directly owns 21,000 shares of the company’s stock, valued at $198,030. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 102,862 shares of company stock valued at $978,045 in the last three months. 8.60% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the company. FMR LLC raised its holdings in Immunome by 0.3% in the 3rd quarter. FMR LLC now owns 4,224,700 shares of the company’s stock worth $61,765,000 after purchasing an additional 13,757 shares during the period. Janus Henderson Group PLC grew its holdings in Immunome by 10.3% during the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock valued at $50,971,000 after buying an additional 324,614 shares in the last quarter. Marshall Wace LLP raised its position in shares of Immunome by 228.5% during the second quarter. Marshall Wace LLP now owns 1,713,325 shares of the company’s stock valued at $20,731,000 after buying an additional 1,191,774 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Immunome by 13.6% in the third quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock worth $17,657,000 after buying an additional 144,557 shares in the last quarter. Finally, Victory Capital Management Inc. grew its stake in Immunome by 48.1% during the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock valued at $10,684,000 after acquiring an additional 237,497 shares in the last quarter. Institutional investors own 44.58% of the company’s stock.
Immunome Company Profile
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company’s clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Read More
Receive News & Ratings for Immunome Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Immunome and related companies with MarketBeat.com’s FREE daily email newsletter.